Dry eye disease is a common condition linked to tear film instability and meibomian gland dysfunction. Understanding symptoms of dry eye, MGD symptoms, and available dry eye treatment options is essential for effective clinical management.
This page answers common questions about dry eye treatments, including how Tixel Thermo-Mechanical Action technology supports in-office procedures without relying on traditional dry eye laser treatment systems.
Tixel is a medical treatment that uses Thermo-Mechanical Action (TMA) to help manage symptoms of Dry Eye Syndrome by supporting eyelid function and meibomian gland activity.
It delivers controlled thermal energy to the eyelid area, supporting meibomian gland function and tear film stability without using laser technology.
No. Tixel is not a laser. It uses Thermo-Mechanical Action (TMA), a controlled heat-based technology designed for precise clinical application.
It is commonly used for Dry Eye Syndrome, meibomian gland dysfunction (MGD), evaporative dry eye, and chronic ocular surface discomfort.
Patients with moderate to severe symptoms of Dry Eye Syndrome, especially those with meibomian gland dysfunction, are typically good candidates.
Yes. It is designed for clinical environments and can be integrated into existing dry eye treatment workflows.
A standard clinical treatment room and the device itself are required. No complex infrastructure is typically needed.
Yes, clinicians receive training on protocols, safety settings, and patient selection before using the device independently.
Tixel uses Thermo-Mechanical Action (TMA), while IPL uses light-based energy. Both are used in dry eye management but operate through different mechanisms.
The number of sessions depends on severity of Dry Eye Syndrome and the physician’s treatment protocol.
Clinicians often report improvements in tear film stability, gland function, and overall symptom relief in treated patients.1,3,4
Yes. It can be used alongside lubricants, prescription drops, or other physician-directed dry eye treatments.
Clinics typically receive onboarding, training, and clinical guidance for proper device use and protocol implementation.
It offers a Thermo-Mechanical Action approach, providing clinics with a treatment modality different from laser- or light-based systems.
Yes. Peer-reviewed clinical studies demonstrate statistically significant improvement in signs and symptoms of evaporative dry eye associated with meibomian gland dysfunction, including improvements in tear film stability, patient-reported symptoms, and meibomian gland function.1,3,4
Some patients report symptom improvement within a few weeks, depending on severity and treatment protocol.
Yes. It is designed for controlled application on the periocular area under professional clinical supervision.
Yes. It is designed to support meibomian gland activity, which plays a key role in tear film stability.
Yes. It is commonly used in cases of evaporative Dry Eye Syndrome associated with meibomian gland dysfunction.
It allows clinics to expand their dry eye treatment offerings, improve patient outcomes, and integrate additional technology into their practice.
Yes. It can be included as part of a long-term, physician-directed dry eye management plan.
Downtime is typically minimal, but post-treatment effects depend on individual patient response and clinical protocol.
No. It is intended as part of a comprehensive dry eye management strategy, not a standalone replacement for all therapies.
Request a demo or contact our team to learn more about Tixel-i.